Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS)
- Previous Close
14.51 - Open
14.65 - Bid 14.79 x --
- Ask 14.80 x --
- Day's Range
14.52 - 15.00 - 52 Week Range
9.79 - 18.64 - Volume
6,467,875 - Avg. Volume
5,524,767 - Market Cap (intraday)
6.265B - Beta (5Y Monthly) 0.34
- PE Ratio (TTM)
24.65 - EPS (TTM)
0.60 - Earnings Date --
- Forward Dividend & Yield 0.21 (1.44%)
- Ex-Dividend Date Jun 24, 2024
- 1y Target Est
--
Sichuan Huiyu Pharmaceutical Co., Ltd. research and develops, produces, and sells anti-tumor and injection drugs in China and internationally. The company offers injection drug products, such as pemetrexed disodium, methrotraxate, docetaxel, azacitidine, oxaliplatin, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, palonosetron hydrochloride, plerixafor, levetiracetam concentrated solution, sodium valproate concentrated solution, epirubicin hydrochloride, fulvestrant, milrinone, fluorouracil, sodium thiosulfate, zoledronic acid, zoledronic acid concentrated solution, cisatracurium besylate, bortezomib, octreotide acetate, doxorubicin, and palonosetron hydrochloride. Sichuan Huiyu Pharmaceutical Co., Ltd. was incorportaed in 2010 and is headquartered in Neijiang, China.
www.huiyupharma.com1,382
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 688553.SS
View MorePerformance Overview: 688553.SS
Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 688553.SS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 688553.SS
View MoreValuation Measures
Market Cap
6.27B
Enterprise Value
3.93B
Trailing P/E
24.65
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.75
Price/Book (mrq)
1.58
Enterprise Value/Revenue
3.60
Enterprise Value/EBITDA
14.09
Financial Highlights
Profitability and Income Statement
Profit Margin
23.22%
Return on Assets (ttm)
0.90%
Return on Equity (ttm)
6.29%
Revenue (ttm)
1.09B
Net Income Avi to Common (ttm)
253.33M
Diluted EPS (ttm)
0.60
Balance Sheet and Cash Flow
Total Cash (mrq)
2.74B
Total Debt/Equity (mrq)
10.44%
Levered Free Cash Flow (ttm)
38.22M